Enliven Therapeutics Inc ELVN

$41.52 -0.41 (-0.98%)

Valuation

Market cap
3,072,253,000
Revenue TTM
$0
Net income TTM
$-103,690,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,298,500
Avg volume
1,299,230
Day's range
$40.82 – $41.64
Shares out
73,271,000
Stochastic %K
77%
Beta
0.24
Analysts
Strong Sell
Price target
$73.15

Price

Company profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal gro...

Show more

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Industry
Biotechnology
Sector
Healthcare
Phone
720 647 8519
Website
https://www.enliventherapeutics.com
Address
6200 Lookout Road, Boulder, United States

Latest news

Stocktwits

Quantumup Oct 19, 12:40 PM
H.C. Wainwright⬆️ $ELVN's PT to $73 and reiterated Buy after earlier this month, Enliven announced alignment with the FDA on the design of the planned randomized Phase 3 ENABLE-2 trial (expected to start by end-2026), [ $BMY TEVA $NVS PFE TAK TERN - MRK ] which will evaluate relcobatinib (ELVN-001) 80mg QD vs investigator-selected 2nd-generation TKI (i.e., dasatinib, nilotinib, or bosutinib) in 2L+ CML. Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2112161680117444742?s=20
0 replies
prismmarketview Oct 12, 3:14 PM
Oct. 13 is National Metastatic Breast Cancer Awareness Day, which Congress recognized in 2009. It focuses on stage 4 disease, which has no cure. Per advocacy group METAvivor, 20-30% of early-stage breast cancers recur as stage 4, MBC accounts for 98% of breast cancer deaths, and less than 5% of research funding goes to metastatic disease. Emerging biotechs are working on the gap. Names to watch: BriaCell Therapeutics $BCTX (Phase 3 Bria-ABC, interim readout expected this year) Oncolytics Biotech $ONCY (pelareorep, randomized Phase 2) Enliven Therapeutics $ELVN (ELVN-002 in HER2+ MBC, Phase 1) Plus Therapeutics $PSTV (REYOBIQ for leptomeningeal metastases) Prelude Therapeutics $PRLD (Phase 1 planned 2H 2026). These are small-cap, clinical-stage companies with binary trial outcomes, thin liquidity, and likely future capital needs. Most programs are years from potential approval. http://prismmarketview.com/closing-the-gap-emerging-biotechs-take-aim-at-metastatic-breast-cancer/
0 replies
thedentite Oct 9, 2:40 PM
$ELVN Hopefully this is the beginning of our march back up to 78.
0 replies
Quantumup Oct 8, 12:20 PM
Guggenheim reiterated $ELVN Buy-$78 and said -- Guggenheim ELVN shares have been down -28% since 9/1 vs. -7% XBI, which we attribute to profit-taking and lowered investor near-term M&A expectations, rather than a change in company fundamentals. $NVS $MRK Here's what Guggenheim went on to say: https://x.com/Quantumup1/status/2108170557724205462?s=20
0 replies
prismmarketview Oct 7, 1:49 PM
$ELVN: FDA alignment on final design of ENABLE-2, Phase 3 trial of relcobatinib (formerly ELVN-001) in previously treated CML → ~450 adults, 1:1 randomization → Relcobatinib 80 mg QD vs investigator-selected dasatinib, nilotinib, or bosutinib → Primary endpoint: MMR at Week 24; key secondary: MMR at Week 96 → Design target: 10+ percentage-point MMR advantage over control = statistical superiority → Targets BCR::ABL1; company calls it potentially best in class → On track to initiate before year-end 2026 Caveats: investigational, and design alignment is not approval or a guarantee of success. The 10-point figure is a trial design assumption, not a result. No readout date, filing timeline, or revenue forecast. Head-to-head comparison against established TKIs is a high bar. $ELVN #Biotech #Leukemia https://prismmarketview.com/enliven-aligns-with-fda-on-phase-3-leukemia-trial-targets-late-2026-start/
0 replies
thedentite Sep 16, 6:02 PM
$ELVN Am I missing something?
1 replies
mktrdr59 Sep 1, 1:26 AM
$ELVN could be completing three wave corrective pattern that looks like a bull flag.
0 replies
thedentite Aug 28, 10:15 PM
$ELVN Damn I thought I got the bottom. Well, 200 more shares at 58,18. Monday it’ll be 61
0 replies